Abbott to Conduct BE Study for Carbimazole 15 mg, Trial Waiver Granted In India
New Delhi: Abbott Healthcare Pvt. Ltd has received the green signal from the Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) to conduct a bioequivalence (BE) study for its Carbimazole Tablets I.P. 15 mg, while also securing a clinical trial waiver for the formulation.
The decision was taken during the SEC (Endocrinology & Metabolism) meeting held on 24th July 2025, where the firm presented its proposal for grant of permission to manufacture and market two dosage strengths: Carbimazole Tablets I.P. 2.5 mg and 15 mg.
Carbimazole is an antithyroid medication primarily indicated for the treatment of hyperthyroidism, including Graves' disease. It functions by inhibiting the thyroid peroxidase enzyme, thereby reducing the synthesis of thyroid hormones.
During the meeting, Abbott submitted the therapeutic rationale and justification for introducing both strengths. The firm highlighted that the 2.5 mg formulation would allow for more precise dose titration in sensitive patients, helping clinicians minimize the risk of inducing hypothyroidism. Meanwhile, the 15 mg strength was proposed to improve patient compliance by reducing pill burden in those requiring higher doses.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.